ReviewInfection and immunity2010
A decade of Burkholderia cenocepacia virulence determinant research.
Review in Infection and immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 154 citations in OpenAlex.
- Trial
- Optimized cumate toolkit for tunable protein expression duringApplied and environmental microbiology · 2026Article
- Opsonization Improves Dual Proteomic Analysis ofJournal of proteome research · 2026Article
- Long-term lung infection suppression in a mouse model caused via the clinical isolate of Burkholderia cenocepacia using the non-traditional antibacterial agent Fluorothiazinone.The Journal of antibiotics · 2026Article
- Functional analysis ofMicrobiology spectrum · 2026Article
- Laboratory strategies for the identification of Burkholderia species: From classical phenotyping to advanced genomic and proteomic approaches.Antonie van Leeuwenhoek · 2026Review
- Forging biofilms: metal-induced microbial responses in biofilm formation.Journal of bacteriology · 2025Review
- UnravelingmSystems · 2025Article
- Deferiprone inhibits virulence and biofilm formation in Burkholderia cenocepacia.Medical microbiology and immunology · 2025Article
- A type VI secretion system inInfection and immunity · 2024Article
- The mntH gene of Burkholderia cenocepacia influences motility and quorum sensing to control virulence.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Burkholderia cenocepacia epigenetic regulator M.BceJIV simultaneously engages two DNA recognition sequences for methylation.Nature communications · 2024Article
- Glycoproteomic and proteomic analysis ofMicrobiology spectrum · 2024Article
- Article
- Bacteriophage steering ofJournal of bacteriology · 2023Article
- Bacterial type VI secretion system (T6SS): an evolved molecular weapon with diverse functionality.Biotechnology letters · 2023Review
- A machine learning model trained on a high-throughput antibacterial screen increases the hit rate of drug discovery.PLoS computational biology · 2022Article
- TheApplied and environmental microbiology · 2022Review
- Human Cryptic Host Defence Peptide GVF27 Exhibits Anti-Infective Properties against Biofilm Forming Members of thePharmaceuticals (Basel, Switzerland) · 2022Article
- Hospital sink traps as a potential source of the emerging multidrug-resistant pathogenJournal of medical microbiology · 2022Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
The Burkholderia cepacia complex (Bcc) is a group of genetically related environmental bacteria that can cause chronic opportunistic infections in patients with cystic fibrosis (CF) and other underlying diseases. These infections are difficult to treat due to the inherent resistance of the bacteria to antibiotics. Bacteria can spread between CF patients through social contact and sometimes cause cepacia syndrome, a fatal pneumonia accompanied by septicemia. Burkholderia cenocepacia has been the focus of attention because initially it was the most common Bcc species isolated from patients with CF in North America and Europe. Today, B. cenocepacia, along with Burkholderia multivorans, is the most prevalent Bcc species in patients with CF. Given the progress that has been made in our understanding of B. cenocepacia over the past decade, we thought that it was an appropriate time to review our knowledge of the pathogenesis of B. cenocepacia, paying particular attention to the characterization of virulence determinants and the new tools that have been developed to study them. A common theme emerging from these studies is that B. cenocepacia establishes chronic infections in immunocompromised patients, which depend more on determinants mediating host niche adaptation than those involved directly in host cells and tissue damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.